Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.

Trial Details

NCT ID
NCT04070040
Phase
PHASE2
Sponsor
Beijing Sanbo Brain Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Camrelizumab
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • The initial diagnosis was primary diffuse large B-cell lymphoma of the central nervous system confirmed by histopathology;
  • Prior to first-line treatment based on methotrexate (with or without radiotherapy), tumor recurrence was confirmed by MRI;
  • Measurable focus in MRI (\>10x10mm);
  • Aged \> 18 years;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →